Genetic Therapy Revolutionizing Prostate Cancer Treatment: A Comprehensive Analysis of Therapeutic Advancements
Main Article Content
Abstract
Prostate cancer remains a significant global health concern, demanding innovative and effective treatment strategies. In this era of precision medicine, gene therapy has emerged as a groundbreaking approach for the management of prostate cancer. This article provides a comprehensive review of the state-of-the-art research on the application of genetic therapy in the treatment of prostate cancer. We delve into the molecular underpinnings of prostate cancer and the intricate web of genetic alterations that drive its progression. Furthermore, we explore the diverse arsenal of genetic tools, such as CRISPR-Cas9, viral vectors, and RNA interference, which are being harnessed to target and modify prostate cancer-related genes. The article highlights the promise of gene therapy in enhancing treatment outcomes, minimizing side effects, and circumventing therapeutic resistance. Additionally, we discuss the current challenges, ethical considerations, and regulatory aspects surrounding the clinical translation of gene therapy for prostate cancer. Ultimately, this review underscores the transformative potential of genetic therapy in revolutionizing the management of prostate cancer and improving the quality of life for affected individuals.
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
References
I. Hacein-Bey-Abina, S. et al. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 302, 415–419 (2003).
II. High, K. A. & Roncarolo, M. G. Gene therapy. N. Engl. J. Med. 381, 455–464 (2019).
III. Stratton, M. R., Campbell, P. J. & Futreal, P. A. The cancer genome. Nature 458, 719–724 (2009).
IV. Catalona, W. J. et al. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N. Engl. J. Med. 324, 1156–1161 (1991).
V. Cooperberg, M. R., Broering, J. M. & Carroll, P. R. Risk assessment for prostate cancer metastasis and mortality at the time of diagnosis. J. Natl Cancer Inst. 101, 878–887 (2009).
VI. Herman, J. R. et al. In situ gene therapy for adenocarcinoma of the prostate: a phase I clinical trial. Hum. Gene Ther. 10, 1239–1249 (1999).
VII. 7.-Miles, B. J. et al. Prostate-specific antigen response and systemic T cell activation after in situ gene therapy in prostate cancer patients failing radiotherapy. Hum. Gene Ther. 12, 1955–1967 (2001).